Analysts Conflicted on These Healthcare Names: Nektar Therapeutics (NKTR) and BioNTech SE (BNTX)
Nektar Therapeutics Analyst Ratings
Jefferies Adjusts Nektar Therapeutics Price Target to $1 From $0.50, Maintains Hold Rating
Nektar Therapeutics Analyst Ratings
Nektar Therapeutics Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcus Biosciences (RCUS), Aligos Therapeutics (ALGS) and Nektar Therapeutics (NKTR)
Mizuho Reiterates Neutral on Nektar Therapeutics, Maintains $6 Price Target
Nektar Therapeutics Analyst Ratings
Mizuho Securities Sticks to Their Hold Rating for Nektar Therapeutics (NKTR)
SVB Securities Sticks to Its Hold Rating for Nektar Therapeutics (NKTR)
Jefferies Upgrades Nektar Therapeutics (NKTR) to a Hold
Mizuho Securities Sticks to Its Hold Rating for Nektar Therapeutics (NKTR)
SVB Securities Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
Mizuho Securities Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
SVB Securities Sticks to Its Hold Rating for Nektar Therapeutics (NKTR)
Goldman Sachs Remains a Sell on Nektar Therapeutics (NKTR)
Analyst Ratings for Nektar Therapeutics
Oppenheimer Adjusts Nektar Therapeutics Price Target to $3 From $5, Maintains Perform Rating
Nektar Therapeutics (NKTR) Receives a Hold From Oppenheimer
Oppenheimer Maintains Perform on Nektar Therapeutics, Lowers Price Target to $3
No Data
No Data